UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/554,310	05/26/2006	Jean-Marie Houle	280802001300	2639
25225 7590 06/27/2008 MORRISON & FOERSTER LLP			EXAMINER	
12531 HIGH B SUITE 100			FARAH, AHMED M	
SAN DIEGO, CA 92130-2040			ART UNIT	PAPER NUMBER
			3735	
			MAIL DATE	DELIVERY MODE
			06/27/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Comments	10/554,310	HOULE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Ahmed M. Farah	3735				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	-· action is non-final.					
<i>;</i> —	, —					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
		3.3.2.3.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-20</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	· · · · · · · · · · · · · · · · · · ·					
Application Papers						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	• •					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
TT) The datifor declaration is objected to by the Ex-	anniner. Note the attached Office	Action of form FTO-192.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date Notice of Informal Patent Application						
Paper No(s)/Mail Date <u>1/23/2006</u> . 6) Other:						

Art Unit: 3735

DETAILED ACTION

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-15 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-47 of U.S. Patent No. 7,264,629.

Although the conflicting claims are not identical, they are not patentably distinct from each other because they are directed to analogous methods for treatment of hair loss.

Claims 1, 8-11 and 13-15 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 10-16 of U.S. Patent No. 7,090,691. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are directed to analogous methods for treatment of hair loss.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-20 are rejected under 35 U.S.C. 102(e) as being anticipated by Simkin et al. US Patent No. 7,264,629.

Simkin et al. disclose a photodynamic method for increasing the number of terminal hair on the skin of a patient, comprising: administering a photosensitizer agent to an area of the patient's skin where hair growth is desired; and irradiating said area with optical energy containing wavelengths appropriate to activate the agent so as to increase the number of hairs in the treatment area as claimed.

With respect to claims 16-20, Simkin et al. teach the following:

"In another aspect, the invention provides for methods to determine the amount of increase in hair growth mediated by PDT. These methods may be practiced with any photosensitizer in various amounts or concentrations and with use of various irradiation regimens, including, but not limited to, those with variations in timing, radiation energy dose and/or rate, and wavelength of radiation. In one embodiment, such methods comprise

- a) administering a photosensitizer to skin exhibiting hair growth reduction or hair loss;
- b) irradiating said skin with electromagnetic energy containing a wavelength absorbed by said photosensitizer to activate it; and
 - c) measuring the increase in hair growth,

wherein an increase in hair growth in comparison to skin that has not been treated with both a) and b) can be determined. Preferably, the photosensitizer is one which absorbs activating radiation in the range of about 400 nm to about 800 nm and is administered by topical application. Said measuring can be by any means known to the skilled person, including, but not limited to, counting the number of terminal hairs, measuring hair weight, measuring hair density, and/or measuring hair shaft diameter, most preferably by counting the number of terminal hairs. Preferably, the skin that has not been treated has not been treated with one of a) and b)."

Art Unit: 3735

Claims 1-15 are rejected under 35 U.S.C. 102(e) as being anticipated by McDaniel US Patent No. 6,936,044.

McDaniel discloses a photodynamic method for increasing the number of terminal hair on the skin of a patient, comprising: administering a photosensitizer agent to an area of the patient's skin where hair growth is desired; and irradiating said area with optical energy containing wavelengths appropriate to activate the agent so as to increase the number of hairs in the treatment area as claimed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ahmed M. Farah whose telephone number is (571) 272-4765. The examiner can normally be reached on Mon, Tue, Thur and Fri between 9:30 AM 7:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marmor II Charles can be reached on (571) 272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

Application/Control Number: 10/554,310 Page 5

Art Unit: 3735

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ahmed M Farah/ Primary Examiner, Art Unit 3735

June 23, 2008.